GoldenGolden

DiCE Molecules

Small molecule compounds that act by unlocking protein-protein interfaces

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

January 2021
DiCE Molecules raises a $80,000,000 series C round from Agent Capital, Alexandria Venture Investments, Altitude Life Science Ventures, Asymmetry Capital Management, L.P., Driehaus Capital Management, Eventide Asset Management, New Leaf Venture Partners, Northpond Ventures, Osage University Partners, RA Capital Management, Sands Capital Management, Sanofi Ventures and Soleus Capital Management.
January 2021
DiCE Molecules raises a $80,000,000 series C round from Agent Capital, Alexandria Venture Investments, Altitude Life Science Ventures, Asymmetry Capital Management, L.P., Driehaus Capital Management Llc, Eventide Asset Management, New Leaf Venture Partners, Northpond Ventures, Osage University Partners, RA Capital Management, Sands Capital Management, Sanofi Ventures and Soleus Capital Management.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Case study on DiCE Molecules

Axial

Web

May 12, 2020

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Amirah Al Idrus
January 8, 2021
FierceBiotech
DiCE Molecules is setting its sights on the clinic. With $80 million raised from a laundry list of investors led by RA Capital Management, the company will push its lead program, an interleukin-17 antagonist, into a clinical trial in psoriasis and build out its preclinical programs.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.